Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,533
  • Shares Outstanding, K 7,168
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,140 K
  • EBIT $ -20 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2875 +0.97%
on 11/21/25
1.5500 -16.13%
on 12/05/25
-0.2000 (-13.33%)
since 11/14/25
3-Month
1.1000 +18.18%
on 11/07/25
1.7400 -25.29%
on 10/15/25
-0.3000 (-18.75%)
since 09/16/25
52-Week
1.1000 +18.18%
on 11/07/25
21.2400 -93.88%
on 12/17/24
-19.7000 (-93.81%)
since 12/16/24

Most Recent Stories

More News
Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip...

CLDI : 1.3000 (-2.26%)
NVA : 8.14 (+0.37%)
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development...

CLDI : 1.3000 (-2.26%)

Business Summary

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.4020
2nd Resistance Point 1.3776
1st Resistance Point 1.3388
Last Price 1.3000
1st Support Level 1.2756
2nd Support Level 1.2512
3rd Support Level 1.2124

See More

52-Week High 21.2400
Fibonacci 61.8% 13.5465
Fibonacci 50% 11.1700
Fibonacci 38.2% 8.7935
Last Price 1.3000
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar